Simple Summary COVID-19 pneumonia can be confused with Pneumocystis jirovecii pneumonia (PJP) on computed tomography and is a source of misdiagnosis. This can lead to mistreatment and an increased risk of mortality. Gefitinib, a tyrosine kinase inhibitor anti-EGFR used in cancer therapy and corticosteroids, could increase the risk of PJP. Abstract An 82-year-old woman treated for advanced lung cancer with gefitinb was admitted to the emergency unit complaining of dyspnea. Chest computed tomography found abnormalities classified as possible diffuse COVID-19 pneumonia. RT-PCR for Sars-Cov-2 was twice negative. PCR for Pneumocystis jirovecii was positive on bronchoalveolar lavage. The final diagnosis was Pneumocystis jirovecii pneumonia. Therefore, physicians must be careful not to misdiagnose COVID-19, especially in cancer patients on small-molecule therapeutics like gefitinib and corticosteroids.
【저자키워드】 COVID-19, Pneumocystis jirovecii, gefitinib, tyrosine-kinase inhibitor, 【초록키워드】 Corticosteroids, Mortality, Pneumonia, Diagnosis, risk, Cancer therapy, lung cancer, RT-PCR, Computed tomography, PCR, Dyspnea, inhibitor, Bronchoalveolar lavage, cancer patient, tyrosine, increased risk, Final, physician, positive, abnormality, simple, treated,